Search
-
Press releaseMirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and Lic...
Mirum expands potential opportunities across rare disease pipeline and Vivet will lead pre-clinical development of its two gene therapy programs for PFIC3 and PFIC2
-
Press releaseUsing cardio-metabolomic diagnosis to reduce the consequences of obesity
Biotech company OWL Metabolomics develops non-invasive, early diagnosis products for obesity-related diseases
-
Press releaseORYZON starts preclinical collaboration on autism with the Seaver Autism Center at Mount ...
Goal is to explore effects of LSD1 inhibition on animal models of autism in Shank3 deficient mice models
-
Press releaseOur researcher in oncology, Gema Malet, receives a Marie Skłodowska-Curie research grant
In 2020, biologist Gema Malet Engra joined the biotechnology company Laminar Pharmaceuticals after a successful 15-year career in fundamental and applied research in Oncology at several international
-
Press releaseORYZON enrolls first patient in PORTICO
PORTICO is a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder recruiting patients in Europe and the U.S and dedicated to independent assessment of reduction of agitation
-
Press releaseIUL launches iPeak+, the new lateral flow reader for rapid tests
IUL SA launches iPeak+, a new colorimetric off-the-shelf lateral flow reader designed to hold large cassettes. This portable reader is equipped with connectivity and it is able to read cassettes of up
-
Press releaseORYZON publishes vafidemstat first-in-human clinical trial manuscript in CNS Drugs journa...
Vafidemstat displayed good safety and tolerability in healthy young and elderly volunteers
-
Press releaseORYZON to participate in upcoming virtual international conferences in March and April
The company will attend to BIO-Europe Spring 2021, Kempen Life Sciences Conference and the 4 th SACHS Annual Neuroscience Innovation Forum 2021
-
Press releaseORYZON announces successful pre-IND meeting with FDA for the clinical development of vafi...
Oryzon will consequently proceed to file an IND application PORTICO will be developed in several US and European sites
-
Press releaseBIOLAN has launched its rapid serological test for the detection of antibodies against COV...
The Basque SME located in Zamudio has invested heavily to equip itself with the equipment that will allow it to scale up the newly developed product
-
-
Press releaseDrug Developers Can Measure ADCC in Biologically Relevant Systems with New Promega Biolumi...
Promega PBMC ADCC Bioassay combines physiologically representative primary cells with reliable quantitative readout technology
-
Press releaseSIEMENS HEALTHINEERS Y IUL SA, una nueva alianza para combatir la COVID-19
The IUL’s reader, so-called iPeak®, capture, and process the image of the test guaranteeing the objectivity of the interpretation and increasing the sensitivity of the reader of rapid tests
-
Press releaseAseBio brings together top specialized venture capital managers to drive biotech sector
Seven venture capital managers that specialize in the life sciences set up new workgroup as a key instrument for recovery
-
Press releaseORYZON announces FDA Orphan Drug Designation granted to iadademstat for treatment of Acute...
The compound is currently in Phase II Now has orphan designation in both U.S. and EU
-
Press releaseNatac have just opened a process of international recruitment and selection of new profess...
Natac is looking for sales representatives
-
Press releaseZYMVOL and AMINOVERSE team up to develop custom-made alcohol dehydrogenases
Primarily used in the Flavours & Fragrances (F&F) and Fine Chemicals industries, alcohol dehydrogenase is type of enzyme that helps convert alcohols into ketones/aldehydes with exceptionally high
-
Press releaseORYZON to present a corporate update and to hold multiple virtual corporate activities in ...
The company will present recent clinical developments at the H.C. Wainwright Bioconnect, will participate in the 10th Annual Corporate Access Event of LifeSci Advisors 2021, in the open house of
-
Press releaseORYZON Launches Pioneering Schizophrenia Precision Medicine Study In Collaboration With Co...
Goal is to characterize the neuropsychiatric symptoms of patients harboring disease-causing SETD1A gene mutations. Also includes fundamental research in preclinical SETD1A models
-
Press releaseVIVEbiotech winner of the 2020 Gipuzkoa SME Award
-
Press releaseNew H2020 project on ATMPs. Asphalion is the regulatory partner of the ARDAT project
The European Union has awarded a grant of 25.5€ million for the Accelerating Research and Innovation for Advanced Therapies (ARDAT) project.